CellFE Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $22M

  • Investors
  • 15

CellFE General Information

Description

Developer of an intracellular gene delivery platform designed to deliver gene-editing molecules into human cells. The company utilizes a microfluidic device for previously inaccessible cell therapies to provide a means for transporting hard-to-deliver molecules into the cells to treat various disorders, enabling researchers and therapy developers to achieve high yields of healthy cells while maintaining scalability from laboratory discovery to commercial manufacturing.

Contact Information

Website
www.cellfebiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1000 Atlantic Avenue
  • Suite 104
  • Alameda, CA 94501
  • United States
+1 (267)
Primary Industry
Other Devices and Supplies
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1000 Atlantic Avenue
  • Suite 104
  • Alameda, CA 94501
  • United States
+1 (267)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CellFE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A) 14-Jul-2023 $22M Completed Generating Revenue
10. Seed Round Completed Generating Revenue
9. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
8. Grant 31-Dec-2020 Completed Generating Revenue
7. Grant 30-Dec-2020 Completed Generating Revenue
6. Seed Round 31-Mar-2020 Completed Generating Revenue
5. Grant 15-Aug-2019 Completed Generating Revenue
4. Accelerator/Incubator 11-Sep-2018 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2018 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2018 Completed Generating Revenue
To view CellFE’s complete valuation and funding history, request access »

CellFE Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1
Series A-2
Seed-2
Seed-1 6,306,305 $0.000010 8% $1.11 $1.11 1x $1.11 11.85%
Seed 8,991,594 $0.000010 8% $0.69 $0.69 1x $0.69 16.9%
To view CellFE’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

CellFE Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an intracellular gene delivery platform designed to deliver gene-editing molecules into human cells. The co
Other Devices and Supplies
Alameda, CA
20 As of 2026

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CellFE Competitors (1)

One of CellFE’s competitors is Kytopen, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kytopen Venture Capital-Backed Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

CellFE Patents

  • 31

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

CellFE Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250290023-A1 High-throughput mechanoporation for scalable and cost-effective cell therapy manufacturing Pending 15-Mar-2024
WO-2025194040-A1 High-throughput mechanoporation for scalable and cost-effective cell therapy manufacturing Pending 15-Mar-2024
US-20260234558-A1 Methods and systems for rapid engineering of resting cells Pending 05-May-2023
WO-2024233494-A2 Methods and systems for rapid engineering of resting cells Inactive 05-May-2023
WO-2024233494-A3 Methods and systems for rapid engineering of resting cells Inactive 05-May-2023 C12N15/85
To view CellFE’s complete patent history, request access »

CellFE Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CellFE Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
EGB Capital (California) Venture Capital Minority
GreatPoint Ventures Venture Capital Minority
Khosla Ventures Venture Capital Minority
QB3 Accelerator/Incubator Minority
Riverine Ventures Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

CellFE FAQs

  • When was CellFE founded?

    CellFE was founded in 2018.

  • Where is CellFE headquartered?

    CellFE is headquartered in Alameda, CA.

  • What is the size of CellFE?

    CellFE has 20 total employees.

  • What industry is CellFE in?

    CellFE’s primary industry is Other Devices and Supplies.

  • Is CellFE a private or public company?

    CellFE is a Private company.

  • What is the current valuation of CellFE?

    The current valuation of CellFE is .

  • What is CellFE’s current revenue?

    The current revenue for CellFE is .

  • How much funding has CellFE raised over time?

    CellFE has raised $37.8M.

  • Who are CellFE’s investors?

    EGB Capital (California), GreatPoint Ventures, Khosla Ventures, QB3, and Riverine Ventures are 5 of 15 investors who have invested in CellFE.

  • Who are CellFE’s competitors?

    Kytopen is a competitor of CellFE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process